NCT01105247 · OUTCOME

Number of Participants With Treatment Emergent Adverse Events (AEs)

Safety of PCI-32765 in Chronic Lymphocytic Leukemia · Source last updated 2014-03-31

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

What was measured

Number of participants who had experienced at least one treatment emergent AEs.

PCI-32765: 420 mg daily or 840 mg daily

Food-Effect Relapsed/Refractory participants received PCI-32765 420 mg daily

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
PCI-32765	116
Food Effect	16

Source class 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
PCI-32765	116	Not reported	Not reported	Not reported	Not reported
Food Effect	11	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

denoms

description

Number of participants who had experienced at least one treatment emergent AEs.

groups

param Type

NUMBER

reporting Status

POSTED

time Frame

From first dose to within 30 days of last dose of PCI-32765

title

Number of Participants With Treatment Emergent Adverse Events (AEs)

type

PRIMARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice